Clinical trial
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
NCT03168464
Study timeline
Study start (actual)2017-10-09Date precision: day
Registry last updated2023-04-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancer Metastaticunresolved
Interventions
IpilimumabDRUG · verified · RxNorm: ipilimumab
NivolumabDRUG · verified · RxNorm: nivolumab
Radiation therapyRADIATION
Sponsors & collaborators
Weill Medical College of Cornell Universitylead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03168464 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.